Published in Oncology Business Week, May 30th, 2004
The new biorepository, based on the pioneering biomaterials initiative begun 4 years ago by Duke and Ardais, will address the biomaterials requirements of Duke researchers as they conduct a new generation of clinical trials in which cancer is analyzed and treated at the molecular level. While cancer is the initial disease focus of the Biorepository, it will be expanded in the future to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.